Michelle Duquette, PhD

Princeton-based Made Scientific and Southern California-based Basilard BioTech, Inc. announced a strategic collaboration to accelerate the development and translation of Basilard BioTech’s nanomechanical gene delivery platform, Celletto. Celletto addresses long-standing limitations of both viral vectors and conventional non-viral methods. Under the agreement, Basilard BioTech will leverage Made Scientific’s Center of Excellence for Process and Analytical Development and its GMP manufacturing facility. Read more: https://lnkd.in/emde3qzK

13

Curious about the science driving biotech innovation? Biocom California Institute and National University have teamed up to offer a dynamic hybrid course tailored for industry professionals with limited science backgrounds. Explore key concepts like the Central Dogma, Cell Theory and vaccines, and put theory into practice with a hands-on lab experience. Developed by industry experts, this flexible course is the perfect starting point for building your foundation in biotech. Registration opens May 27 Learn more: https://bit.ly/3Z0lBNg

13

Korro Bio is presenting at the 36th International Symposium on ALS/MND in San Diego. Leah Liu, PhD our Associate Director, Target Biology, will share new data in a poster presentation detailing our RNA editing-based therapeutic strategy targeting TDP-43 dysfunction in ALS. Korro Bio’s goal is to potentially: 1. Reduce TDP-43 aggregates: Stabilized TDP-43 variant less likely to form aggregates in cytoplasm 2. Restore nuclear localization: Generate TDP-43 variant with increased nuclear localization 3. Maintain normal splicing: RNA editing reduces mis-splicing in TDP-43 dysfunction model Learn more: https://lnkd.in/eJdz_YK Motor Neurone Disease (MND) Association #ALS #MND #ALSMNDSymp #RNAEditing

71

Intriguing new research from University of Southern California using ultrasound to "switch on" and focus #CARTcell activity on #solidtumors, lower off-target toxicity, and address exhaustion. Reportedly, EchoBack-CAR T-cells can attack tumor cells 5X longer than regular CAR T-cells. Mouse studies so far, but likely more to come. #CellTherapy #Tcells #immunotherapy https://lnkd.in/gESUFu5B

52

4 Comments

𝐖𝐡𝐲 𝐚𝐫𝐞 𝐦𝐚𝐧𝐲 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐬𝐨 𝐮𝐧𝐬𝐭𝐚𝐛𝐥𝐞? That was the key question in our this week´s webinar — and one that continues to challenge many development teams. Bispecifics are incredible in what they can do, but their engineered complexity makes them inherently less stable than traditional antibodies. Structural asymmetry, non-native interfaces, and engineered linkers can all lead to aggregation, high viscosity, and limited shelf life — issues that often surface late in development. Our discussion yesterday showed that the earlier you identify these risks, the more control you gain and smart tools help for a smarter approach: ◆ Early identification of molecular liabilities ◆ Smart predictions using data-driven tools ◆ Shelf-life modeling to guide robust formulation design With the right insights, it’s possible to move from uncertainty to confidence — and build formulations that last. If you missed the session, you can still access our white paper or book a short demo to see how our data science platform supports bispecific formulation. ➤ Download the White paper: https://hubs.li/Q03QTffD0 ➤ Watch a Demo: https://hubs.li/Q03QTfL70 Looking forward to seeing you at our next webinar! #BispecificAntibodies #FormulationScience #Biologics #DrugDevelopment #DataDrivenDevelopment #Leukocare

29

From Target List to Validated AOC Panel: There is a mountain to climb! The AbOliGo team and I wanted to highlight a protocol paper that addresses a critical gap: the long road between choosing your targets and having a working multiplexed panel. The authors know their stuff - for example they published https://lnkd.in/eJVj8Vpt The Problem: While assay such as cyclic immunofluorescence can image 100+ markers, commercial providers offer pre-validated panels that are often too restrictive. Pre-conjugated antibody panels are locked to specific workflows, unusable for other imaging protocols and cannot be customized for specific biological questions or tissue types. Yet building your own panel involves navigating a mountain of optimization steps that most protocols simply skip over. The Solution: This STAR Protocols paper from the Lady Davis Institute at McGill University covers a comprehensive workflow from initial antibody selection through final multiplexed imaging. The protocol covers antibody screening, single-plex validation, fluorophore selection based on antigen abundance, and systematic testing before committing to full panel runs. How were the AOCs made? The protocol used maleimide-thiol conjugation workflow: antibodies are reduced to expose thiol groups, then covalently linked to unique oligonucleotide barcodes. Critically, antibodies must be carrier-free (no BSA or glycerol) for successful conjugation, a requirement that limits available clones. Conjugation is validated by SDS-PAGE gel shift assay, confirming the molecular weight increase from barcode attachment. Key Takeaway: The paper emphasizes that even antibodies validated for standard IF require re-optimization post-conjugation. Staining time, temperature, and concentration may all need adjustment, a reality that underscores how much work lies between "this antibody works" and "this panel works." Kudos to Madelyn Abraham and Sonia V. del Rincon's lab for making this foundational knowledge accessible! As spatial proteomics adoption grows, the availability of ready-to-conjugate AOC reagents will become increasingly important for labs looking to customize panels without starting from scratch. Paper: Gupta et al. STAR Protocols 2025. https://lnkd.in/eFdqGn-z

58

2 Comments

Iambic Therapeutics Co-founder and CEO Thomas Miller will present at the UC San Diego Legends of Science Oncology Symposium (Sept 12) as part of the session “AI in Cancer: Where Are We Going?” Tom will detail how Iambic’s leading AI models for structure-based design and molecular property prediction are accelerating the identification of highly differentiated cancer drug candidates – and highlight IAM1363 – a novel type II HER2 inhibitor for which Iambic will soon share clinical data. Learn more about the program here: https://lnkd.in/giXVcSzq #AI #Drugdiscovery #Oncology #UCSD

105

1 Comment

"Lumen’s technology platform enables therapeutic proteins — traditionally injected or infused — to be produced and delivered orally in an edible, low-cost form. The 110-person company is targeting diseases that act in or originate from the gastrointestinal tract. It recently reported promising Phase 2 results from LMN-201, Lumen Bioscience’s lead candidate for recurrent C. difficile infection. The company also announced that Jeff Raikes, former Microsoft president and Gates Foundation CEO, joined Lumen’s board as an independent director." #seattle #biotech #funding #leadership

13

1 Comment

Looking to learn more about how automation is transforming long-read transcriptomics? Catch up with our latest webinar where Dr. Rebecca Martin, Scientific Lead of the Genomics and Spatial Biology CoLab at Seattle Children's Research Institute demonstrated her team’s implementation of PacBio's Kinnex™ RNA library prep on the SPT Labtech firefly® liquid handler, showcasing how automation enables scalable, reproducible, and high-quality RNA sequencing workflows. Key learning objectives: ✔️Understand how automation improves long-read RNA sequencing workflows: Learn how integrating PacBio's Kinnex™ RNA library prep kit with the firefly® liquid handler enhances consistency, scalability, and quality in transcriptomic research. ✔️Explore the benefits of preserving full-length transcripts with long-read sequencing: Gain insight into how Kinnex and PacBio Iso-Seq enable high-resolution isoform detection—crucial for studying gene expression, splicing, and regulatory elements. ✔️Learn how automated workflows support large-scale transcriptomics projects: See how this automation was applied in the 1000 Genomes Long Read Project to process diverse samples at scale, generating open-access data for the research community. Catch up now 🔗 https://lnkd.in/gvSsvkpk #LabAutomation #LiquidHandling #Genomics

13

Low attomole detection of standard peptides with > 5 orders of dynamic range. The latest workflow powered by the Evosep Eno platform delivers: - Fully automated plasma-to-digest sample processing, seamlessly integrating with low-flow LC-MS for high-throughput analysis - Quantification down to low attomole (amol) levels with >5 orders of dynamic range >90% quantitative accuracy, even in complex plasma backgrounds, verified across serial dilution series - Outstanding assay robustness and repeatability over 200+ consecutive samples, with retention time SD < 0.5 seconds and highly symmetrical peaks - The ability to detect and quantify protein biomarkers for cancer, kidney, and liver diseases, as well as FDA-approved targets This standardized, scalable workflow moves us closer to routine, cost-effective plasma biomarker measurement at scale—bridging the gap from discovery to clinical relevance. The full application note can be downloaded here: https://lnkd.in/eNYmsX3y Evosep Biosystems Waters Corporation #proteomics, #biomarkers, #automation #LCMS #ClinicalResearch

23

2 Comments

It’s exciting to see the San Diego Business Journal spotlight 10x’s acquisition of Scale Biosciences. By combining the power of 10x and Scale, we’re thrilled to broaden the capabilities of our existing and future products, which will help expand the access of powerful, affordable single cell analysis to even more researchers worldwide. 📰 Check out the story: https://bit.ly/4maT0xo

107

1 Comment